232 related articles for article (PubMed ID: 9213916)
1. [Liver injury under tuberculostatic treatment].
Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
[TBL] [Abstract][Full Text] [Related]
2. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
4. Antituberculosis agents.
Goldberger MJ
Med Clin North Am; 1988 May; 72(3):661-8. PubMed ID: 3280912
[TBL] [Abstract][Full Text] [Related]
5. [A clinical investigation of seven patients with pulmonary tuberculosis who developed mixed liver injury during oral anti-tuberculosis treatment].
Nomi F; Hosaka K; Kurosawa T
Kekkaku; 2013 Sep; 88(9):647-51. PubMed ID: 24298690
[TBL] [Abstract][Full Text] [Related]
6. [Case of fatal liver failure due to anti-tuberculous therapy].
Harada Y; Kawakami K; Koyama K; Yamaryo T; Kimura Y
Kekkaku; 2007 Sep; 82(9):705-9. PubMed ID: 17969987
[TBL] [Abstract][Full Text] [Related]
7. [Eruption after the 1st dose of standard antitubercular chemotherapy. Thoughts on pyrazinamide].
Radal M; Jonville-Bera AP; Van-Egroo C; Carré P; Lemarié E; Autret E
Rev Mal Respir; 1998 Jun; 15(3):305-6. PubMed ID: 9677642
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
[TBL] [Abstract][Full Text] [Related]
9. [Isoniazid-induced hepatic failure. Report of a case].
Pereira RM; Tresoldi AT; Hessel G
Arq Gastroenterol; 2000; 37(1):72-5. PubMed ID: 10962632
[TBL] [Abstract][Full Text] [Related]
10. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
11. [-Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-].
Olivier C; Radal M; Mazaud S; Jonville-Béra AP; Martel C; Autret E
Arch Pediatr; 1998 Mar; 5(3):289-90. PubMed ID: 10327997
[TBL] [Abstract][Full Text] [Related]
12. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
[TBL] [Abstract][Full Text] [Related]
13. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
[TBL] [Abstract][Full Text] [Related]
14. Pyrazinamide-induced granulomatous hepatitis.
Knobel B; Buyanowsky G; Dan M; Zaidel L
J Clin Gastroenterol; 1997 Jun; 24(4):264-6. PubMed ID: 9252856
[TBL] [Abstract][Full Text] [Related]
15. Olfactory disturbance related to pyrazinamide.
Tsou CC; Chien JY
QJM; 2014 Mar; 107(3):217-8. PubMed ID: 24023071
[No Abstract] [Full Text] [Related]
16. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
[TBL] [Abstract][Full Text] [Related]
17. Hepatic complications of antituberculosis therapy revisited.
Cohen CD; Sayed AR; Kirsch RE
S Afr Med J; 1983 Jun; 63(25):960-3. PubMed ID: 6857425
[TBL] [Abstract][Full Text] [Related]
18. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
Vu D; Macdonald L
CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338
[No Abstract] [Full Text] [Related]
19. [Clinically apparent liver damage during brief tuberculosis therapy].
Estay S; Armas Merino R; Vega C; Soto JR
Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017
[No Abstract] [Full Text] [Related]
20. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
